Evaluation of Off-Label Recombinant Activated Factor VII for Multiple Indications in Children
نویسندگان
چکیده
منابع مشابه
Off-Label Use of Recombinant Activated Factor VII (NovoSeven®)
NovoSeven® (Novo Nordisk, Denmark) is a recombinant DNA preparation of activated blood coagulation factor VII (rFVIIa). It is used to manage bleeding in hemophilia patients for whom standard therapy is inadequate because of the presence of inhibitors to either factor VIII (hemophilia A) or factor IX (hemophilia B). It poses no risk for the transmission of human pathogens, and it is infused in r...
متن کاملAn Evaluation of Off-Label Use of Recombinant Activated Human Factor VII (NovoSeven)
INTRODUCTION Recombinant activated coagulation factor VII (rFVIIa) is a hemostatic agent developed by Novo Nordisk Pharmaceuticals, Inc., under the trademark NovoSeven. It is a recombinant DNA preparation of a naturally occurring protease, activated blood coagulation factor VII. It is nearly identical to plasmaderived activated factor VII in its pharmacokinetics, structure, and function. The FD...
متن کاملThe hemostatic profile of recombinant activated factor VII. Can low concentrations stop bleeding in off-label indications?
BACKGROUND High concentrations of recombinant activated factor VII (rFVIIa) can stop bleeding in hemophilic patients. However the rFVIIa dose needed for stopping haemhorrage in off-label indications is unknown. Since thrombin is the main hemostatic agent, this study investigated the effect of rFVIIa and tissue factor (TF) on thrombin generation (TG) in vitro. METHODS Lag time (LT), time to pe...
متن کاملComprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery.
BACKGROUND This observational study sought to identify the off-label use pattern of recombinant activated factor VII (rFVIIa) in cardiac surgery and to identify predictors of its effectiveness and risk. METHODS AND RESULTS At 18 Canadian centers, 522 nonhemophiliac cardiac surgical patients received rFVIIa during the period 2003 through 2006; data were available, and retrospectively collected...
متن کاملEvaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study)
Background: Recombinant activated factor VII induces hemostasis in patients with coagulopathy disorders. AryoSeven™ as a safe Iranian Recombinant activated factor VII has been available on our market. This study was performed to establish the safety of AryoSeven on patients with coagulopathy disorder. Methods: This single-center, descriptive,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical and Applied Thrombosis/Hemostasis
سال: 2007
ISSN: 1076-0296,1938-2723
DOI: 10.1177/1076029607302402